Celerion, a global leader in early clinical research, is proud to announce its commitment to the Science Based Targets Initiative (SBTi), reinforcing its dedication to sustainable corporate climate action. By aligning with the SBTi and its ambitious goals, Celerion aims to set both Near Term and Net Zero company-wide emission reduction targets in line with science-based standards.

Committing to the SBTi, Celerion pledges to align its operational strategies with the urgent call for climate action. “Celerion is excited to be on the forefront of this important initiative and look forward to partnering with our clients to build a better future for our global community,” said Celerion CEO Susan Thornton, Ph.D.

The SBTi is a coalition formed by leading climate action organizations, including the CDP, the United Nations Global Compact, the We Mean Business Coalition, the World Resources Institute (WRI), and the World Wide Fund for Nature (WWF). Their mission is to enable companies and financial institutions worldwide to commit to ambitious emissions reduction targets in support of limiting global temperature rise to 1.5°C and achieving net-zero by 2050. The SBTi develops robust standards, tools, and guidance necessary for organizations to effectively meet these objectives.

“Celerion’s commitment to the SBTi is part of our broader vision for sustainable development and environmental stewardship,” said Thornton. “With our expertise and resources, we are not only focused on driving excellence in clinical research but also on contributing to global efforts in combating climate change.”

With this commitment, Celerion joins other leading pharmaceutical and biotechnology companies in taking proactive steps to reduce greenhouse gas emissions, thereby underscoring its leadership in responsible business practices. The company remains eager to collaborate with stakeholders and clients to foster innovations that align with the shared goal of a sustainable future.

About Celerion

Celerion, a global leader in early clinical research, offers clients expert-driven services that enable fast, informed decisions in drug development. With over 50 years of experience, Celerion specializes in Phase 1 studies, including first-in-human dose escalation, drug-drug interactions, cardiac safety, bioequivalence, metabolism, and pharmacokinetics in patient populations. Celerion also provides comprehensive data management, biostatistics, clinical monitoring, and bioanalytical services. For more information, visit www.celerion.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241204329435/en/